Pfizer, riding high on COVID windfall, eyes $5B play for Global Blood Therapeutics

Riding high on its COVID-19 windfall, Pfizer has been busy scouring the biopharma landscape for assets to bring into the fold. Now, the drugmaker appears to have set its sights on Global Blood Therapeutics and its marketed sickle cell disease drug Oxbryta.